Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Osteoarthritis Pain
Latest Information Update: 10 Jul 2024
At a glance
- Drugs LY 3857210 (Primary)
- Indications Pain
- Focus Therapeutic Use
- Acronyms OA05
- Sponsors Eli Lilly and Company
Most Recent Events
- 11 Jul 2023 Status changed from active, no longer recruiting to completed.
- 20 May 2023 Planned End Date changed from 13 Jun 2023 to 14 Jun 2023.
- 20 May 2023 Planned primary completion date changed from 30 May 2023 to 31 May 2023.